ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 838

The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?

Elena Myasoedova1, Arun K. Chandran2, Birkan İlhan3, Brittny T. Major4, C. John Michet III2, Eric L. Matteson2 and Cynthia S. Crowson4, 1Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, 4Health Sciences Research, Mayo Clinic, Rochester, MN

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Disease Activity, remission and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects I: Cardiovascular Disease Risk

Session Type: Abstract Submissions (ACR)

Background/Purpose

Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on CVD risk are lacking. We aimed to examine the impact of RA flare, remission, and cumulative burden of RA severity on CVD in RA.

Methods

In a population-based cohort of patients with RA (age≥30 years; 1987 ACR criteria met in 1988-2007) with no history of CVD we performed a retrospective medical records review of each clinical visit to estimate flare/remission status. RA flare was defined as any worsening of RA activity leading to initiation/change/increase of therapy (OMERACT 9). Remission was defined as the absence of disease activity (i.e. tender joint count [TJC]=0 + swollen joint count [SJC]=0 + ESR<10 mm/hr) (OMERACT 7). The previously validated RA medical Records-Based Index of Severity (RARBIS) and Claims-based Index of RA Severity (CIRAS) were used to estimate RA severity. Data on joint surgeries, erosions, extra-articular manifestations, RA flares, morning stiffness, rheumatoid factor (RF), acute phase reactants, antirheumatic drugs were gathered to calculate RARBIS. Claims data were used to calculate the CIRAS based on the number of rheumatology visits, rehabilitation visits; tests for inflammatory markers, RF, platelet counts, chemistry panels. The comparison cohort included age- and sex-matched non-RA subjects without CVD from the same underlying population. Data on CVD risk factors and incident CVD (i.e. myocardial infarction, cardiovascular death, angina, heart failure, stroke, intermittent claudication) were collected. All subjects were followed until death, migration or 07/01/2012. The association of RA activity/severity measures with CVD was examined using Cox models with time-dependent covariates, adjusting for age, sex, calendar year of RA, CVD risk factors and antirheumatic drug use.

Results

The study included 525 RA patients and 524 non-RA subjects (mean age 54.5 yrs; 71% female in both groups). During the mean follow-up of 10.3 years in RA cohort and 8.8 years in the non-RA cohort, 129 RA patients and 77 non-RA subjects developed CVD. There was a significant increase in CVD risk in RA per each acute flare vs remission (hazard ratio [HR] 1.07 per 6-week flare; 95% confidence interval [CI] 1.01-1.15). The CVD risk for RA patients during remission was not significantly different from the non-RA subjects adjusting for age, sex and calendar year (HR 0.90; 95%CI 0.51-1.59). Increased cumulative moving average of daily RARBIS (HR 1.16, 95%CI 1.03-1.30) and CIRAS (HR 1.38, 95%CI 1.12-1.70) was associated with CVD. RA patients who spent more time in medium and high CIRAS tertiles tended to have higher CVD risk vs those in the lower tertile (HR 1.08, 95%CI 0.98-1.20 and HR 1.18, 95%CI 1.06-1.31, respectively, per 1yr increase).

Conclusion

There was a meaningful 7%-increase in CVD risk with the exposure to each acute flare, but not remission, in RA vs general population highlighting the pivotal role of RA flares in shaping CVD risk in RA. Higher long-term burden of RA severity was associated with significantly increased CVD risk in RA suggesting accrued detrimental impact of RA severity over time.


Disclosure:

E. Myasoedova,

Roche Pharmaceuticals,

2;

A. K. Chandran,

Roche Pharmaceuticals,

2;

B. İlhan,
None;

B. T. Major,

Roche Pharmaceuticals,

2;

C. J. Michet III,
None;

E. L. Matteson,
None;

C. S. Crowson,

Roche Pharmaceuticals,

2.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-rheumatoid-arthritis-disease-activity-on-cardiovascular-disease-risk-what-is-the-role-of-the-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.